Eyeworld

Learn more at XDEMVYHCP.com Patients treated with XDEMVY experienced collarette reduction to ≤2 collarettes (Grade 0) at Day 43 6 Vehicle XDEMVY Proportion of patients achieving collarette reduction (≤2 collarettes) SATURN-1 SATURN-2 12% 55% SATURN-2* SATURN-1* 7% 44% P<0.01 P<0.01 Patients treated with XDEMVY experienced collarette reduction to ≤2 collarettes (Grade 0) at Day 43, consistent with the results seen in the clinical trials 6,7 Improvement in number of meibomian glands yielding liquid secretion (MGYLS) at Day 43 in patients treated with XDEMVY vs baseline (P<0.01) 7 References: 1. Fromstein SR et al. Clin Optom (Auckl). 2018;10:57-63. 2. Liu J et al. Curr Opin Allergy Clin Immunol. 2010;10(5):505-510. 3. Trattler W et al. Clin Ophthalmol. 2022;16:1153-1164. 4. Zhang XB et al. Int J Ophthalmol. 2018;11(4):589-592. 5. American Association for Pediatric Ophthalmology & Strabismus. Updated March 2023. Accessed December 4, 2024. https://aapos.org/glossary/meibomian-gland- dysfunction-and-treatment 6. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023. 7. Data on file, Tarsus Pharmaceuticals, Inc. * In SATURN-1 and SATURN-2, the safety and efficacy of XDEMVY for the treatment of DB were evaluated in a total of 833 patients (415 of whom received XDEMVY) in two 6-week, randomized, multicenter, double-masked, vehicle-controlled studies. Patients were randomized to either XDEMVY or vehicle at a 1:1 ratio, dosed twice daily in each eye. 6 † ERSA was a randomized pilot study evaluating the safety and efficacy of XDEMVY administered twice daily, ~12 hours apart, for the treatment of DB patients with MGD (n=20). 6,7 INDICATIONS AND USAGE XDEMV Y (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis. IMPORTANT SAFETY INFORMATION: WARNINGS AND PRECAUTIONS Risk of Contamination: Do not allow the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration. © 2025 Tarsus Pharmaceuticals, Inc. Tarsus, XDEMVY, and the associated logos are registered trademarks of Tarsus Pharmaceuticals, Inc. US––2400520 1/25 To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals, Inc. at 1-888-421-4002 or the FDA at 1-800-FDA-1088 (www.fda.gov/medwatch). Please see next page for a Brief Summary of the full Prescribing Information. ADVERSE REACTIONS: The most common adverse reaction with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/ hordeolum and punctate keratitis. Demodex mites cause inflammation, a key component of Demodex blepharitis (DB) and meibomian gland disease (MGD) 1,2 Meibomian gland obstruction and inflammation, triggered by Demodex mites, can result in patient symptoms, such as 1,2,4,5 : ∙ Fluctuating vision ∙ Itching ∙ Redness There were no treatment-related serious adverse events. 7 In SATURN-1/SATURN-2 clinical trials*: In the pilot ERSA study † : of patients with MGD also have DB (the presence of collarettes) 3 This is not the actual product. It is a depiction of the product for dramatic purposes.

• Cover